Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
TuHURA Biosciences, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Bristol-Myers Squibb
M.D. Anderson Cancer Center
USWM, LLC (dba US WorldMeds)
Memorial Sloan Kettering Cancer Center
Modulation Therapeutics, Inc.
NRG Oncology
Replimune Inc.
Pfizer
Centre Hospitalier Universitaire de Nice
Aulos Bioscience, Inc.
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)